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Negotiating consortium agreements is often a challenging endeavour. The common interests and 
objectives in setting up a successful R&D collaboration in a cutting edge research area are generally 
clear. However, due to the variety of negotiating partners with different interests, objectives and 
prior commitments, intellectual property (IP) ownership, access rights, IP valuation, project 
management, liability and post project issues tend to remain considerable hurdles. 
These hurdles were discussed at the KU Leuven on 3 May 2013 during the workshop Consortium 
Agreements for R&D Projects in the Life Sciences Sector’ which was organized as part of the Quinz 
Global Law School. The debate was initiated by an expert panel consisting of top level 
representatives from the pharmaceutical industry, academia, biotech companies, technology transfer 
offices (TTOs) and contract research organizations. This report seeks to provide a summary of the 
constructive discussion, some conclusions and a number of solutions for issues which are currently 
experienced in industry. The main topics covered by the workshop are the benefits to enter into 
publicly funded consortia, the challenges in establishing a consortium, issues relating background 
and foreground IP and in particular co-ownership, the specific nature of universities in consortia and 
the issue of publication. 
The panel consisted of: Inge Basteleurs (General Counsel Biocartis), Daphné Derouane (Senior patent 
counsel UCB), Michel Detheux (Co-founder & CEO iTEOS Therapeutics), Bruno Lambrecht (Head Legal 
Department LRD), Vincent Lannoy (Euroscreen), Olivier Lescroart (LRD), Bart Lintermans (Partner at 
Quinz), Kevin Nachtrab (President of the Licensing Executives Society International and Senior IP 
Attorney at Johnson & Johnson), Sean O’Connor (Professor University of Washington School of Law), 
Magali Pinot (Legal Manager IMI), Ilse Samoy (Professor Institute for the Law of Obligations, KU 
Leuven), Annie Van Broeckhoven (CEO Q-Biologicals), An Van Den Broecke (Innovation Manager TTO 
UGent), Esther Van Zimmeren (Post-doctoral Researcher Centre for Intellectual Property Rights 
(CIR)), Christophe Verbruggen (Director Legal Affairs, Jansen Pharmaceutica) and Pieter Wyckmans 
(Partner at Quinz, moderator). 
 
1. Benefits to enter into publicly funded consortia 
There are many benefits in establishing publicly funded consortia. These benefits mainly relate to 
funding, risk sharing, access to new knowledge and networking opportunities. For large companies, 
attracting public funding is especially important to be able to engage in innovative research and to 
set up risky research projects. For academia, attracting public funding is also the most important 
aspect. Attracting public funding is not the most important reason for Small and Medium-sized 
Enterprises (SMEs) to collaborate in publicly funded consortia, as normally only 75% of the research 
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costs are covered, which may cause great budgetary challenges for SMEs. All parties value the 
networking aspects and the concentration of specific knowledge, know-how and expertise in the 
consortium. 
 
2. The Challenges in establishing a (publicly funded) consortium 
The greatest challenge in establishing a consortium is finding your way through the maze of funding 
schemes, which exist in Flanders and at the EU level. Special knowledge and expertise is often 
required to understand and correctly use the schemes. Furthermore, every funding scheme has its 
own specifics, including its own rules related to IP, such as access to background IP, use rights, 
membership, termination possibilities, etc. 
It can therefore be hard to identify the most appropriate funding scheme for a certain research 
project. Often, not all participants to a publicly funded consortium are aware of the consequences 
related to a particular type of collaboration. This can result in different expectations between 
participants. It is considered important to actively and consciously manage the expectations of the 
parties in consortium agreements. Clear communication of the expectations by all the parties 
involved is therefore absolutely necessary. 
For large companies the question regarding the source of the funding seems to be less important. 
They have the necessary expertise to understand the funding schemes in-house and they focus on 
the beneficial and innovative results of the research and the desired output of the research. For 
instance whether it will be basic chemistry or a final product in deciding on the type of funding and 
the need for further collaboration. SMEs, and in particular start-up companies in the life sciences that 
are involved in clinical trials, are generally more concerned about getting to a stable source of 
funding, as this will enable them to carry out the various stages of the clinical trials. 
In the United States there has been a discussion on the type of research that should be carried out 
with public funding. Public funding is usually intended for early stage research where the outcome 
will then become a ‘public good’. When the research is closer to the commercial stage, parties will 
rather use corporate sponsored consortium agreements and will consider public funding only as a 
last resort. 
 
3. Ownership Foreground IP 
In private consortium agreements funded by industry participants, the question arises whether the IP 
ownership should vest with the party that generates the foreground IP or with the party that funds 
the project. However, not all negotiations concerning foreground IP are dominated by ownership 
issues. Several panel members argue that participants are often unable to explain why they need full 
ownership of the foreground IP. Therefore, it is essential that in preparation of the negotiations one 
considers whether exclusive ownership is required in order to accomplish the objectives of the 
consortium and their goals in the exploitation phase. Exclusive ownership is not always necessary to 
benefit from the foreground IP. However, every party wants some form of compensation for their 
efforts in the consortium. 
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Most consortia in the life sciences are nowadays precompetitive. In early stage projects, access to 
high-level expertise and infrastructure, freedom to operate, exclusivity and a right of first offer or a 
right of first refusal may be equally important as ownership of the results and the associated 
foreground IP. The added value of the consortium is not mainly related to IP ownership, but in the 
access to and use of the foreground IP from which competitors are excluded. Large pharmaceutical 
companies increasingly require exclusivity, e.g. on a molecule, rather than IP ownership, because 
they want to circumvent the fiduciary duties that correspond with ownership. As a result of these 
changing preferences, in a collaboration between industry and academia, it becomes more common 
for the generators (usually universities) to obtain ownership of foreground IP. If the objective of the 
research is not precompetitive, but focused on an end-product , industry partners will generally be 
reluctant to conduct the research within the framework of a consortium. In case parties will attempt 
to set up a consortium anyway, the negotiations on the consortium agreement about IP ownership 
will become much harder. In the United States, the tax exempt status of most universities prohibit 
them from pre-assigning any inventions developed under sponsored research or consortium 
agreements, especially when work is to be done in tax exempt bond financed facilities. Likewise, 
universities generally cannot precommit to an exclusive license to the private consortia members 
either, for the same reasons. Finally, if any federal public funding is involved in the research, then the 
Bayh-Dole Act governs the disposition of inventions. 
 
4. Co-ownership 
For industry, co-ownership of IP is often difficult to manage, certainly when the IP would be related 
to an end product. Moreover, co-ownership creates a complex legal environment with respect to a 
variety of legal domains such as tax law, IP law, bankruptcy law and competition law. With respect to 
co-owned IP, the rules regarding exploitation and licensing may differ from country to country and 
sometimes different regimes exist with respect to copyright and patent law. In some countries 
exploitation or the grant of an (exclusive) license are only possible after the consent of the co-
owners. This may seriously delay or even block further commercialization of the innovations. An 
alternative to co-ownership would be to establish a joint-venture, which would obtain ownership of 
the IP and give grant back licenses to the parties. However, the establishment of a joint-venture 
requires more formalities than ‘simple’ co-ownership of the IP and the joint-venture should 
preferably remain relatively small in order to be manageable. 
For academia, however, co-ownership is a relatively common solution. Universities strive to have fair 
co-ownership agreements. There are no clear-cut rules of what would constitute a fair agreement: 
fairness can only be assessed on a case-by-case basis. The comments about ownership of university 
developed IP in Section 4 above, apply equally in the co-ownership situation.  
 
5. Background IP 
Granting access to background IP is an essential part of each consortium agreement: without such 
(mutual) access, the cooperation serves no purpose. The terms of such access agreements are either 
determined by funding schemes imposed by public authorities or, in the absence thereof, by the 
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parties themselves during the negotiations. In this area, there is a strong need for legal certainty, 
because use of foreground IP might infringe background IP or third parties’ rights, hence impeding 
the research within the framework of the consortium.  
There are two ways of ensuring legal certainty: either by negotiating a negative list of background IP 
which is not to be used, or by providing a positive list which includes all background IP that can be 
used. The parties will determine which kind of list is most suitable for a given agreement. E.g. some 
parties prefer a negative list when their IP has particular commercial value, so that they can indicate 
clearly which assets are beyond the scope of the consortium agreement.  
 
6. Specific nature of universities 
A specific characteristic of universities is their non-hierarchical structure based on the notion of 
academic freedom. Unlike companies which have a scientific officer who determines the research 
strategy, universities do not have one widely-supported research strategy, but a variety of bottom up 
initiatives. It is essential for universities to limit the obligations created by way of a research 
collaboration agreement to the specific department involved in and benefiting from the agreement, 
for instance with respect to access and use of background IP. 
The industry representatives recognize the importance of this specific characteristic but stress the 
need for legal certainty and freedom to operate. They tend to expect a high degree of 
professionalism and organization from universities. It should, for instance be avoided at all times that 
another research group of the same university would acquire a blocking patent. 
The university representatives acknowledge the need for legal certainty and freedom to operate and 
argue that the best guarantee they can offer is ‘internal hygiene’. An effective TTO should have a 
central and good overview of the university’s IP portfolio. Such internal hygiene would avoid 
problems of freedom to operate caused by other departments from the same university. Moreover, 
researchers who receive external funding from a private or public source have a responsibility not to 
disclose information they get from their commercial partners. Academic freedom can never serve as 
a valid justification for leaking confidential information. Corporate sponsored research necessarily 
entails a certain limitation of academic freedom. 
In the United States, the assignment of IP to commercial partners is controversial. Universities tend 
to require a reservation of rights for research use for other researchers across the university and 
sometimes even for all US universities when rights are transferred to a company. Another problem is 
that state universities are not willing to waive their sovereign immunity, which renders it difficult to 
take action in case they are involved in IP infringements even though the same state universities 
have started infringement procedures against private actors.1 A body of case-law is evolving in this 
area and has received a lot of attention. 
 
                                                          
1 Note that once a state university initiates IP litigation against a private actor, it has waived sovereign 




The issue of publication is not new, but continues to raise some challenges in the management of 
consortia because of the different interests which are at stake. Whereas companies are looking for 
ways to monetize the outcome of the research by applying for patents, the priority for universities is 
still for valorisation in the form of publications even though universities increasingly apply for patents 
themselves as well. For industry, the problem is that publications end up in the public domain and 
create prior art which may limit or even render it impossible to get a patent with respect to the 
related inventions. However, for academia, it is important to have scientific priority, i.e. to be the 
first one to publish the research results in a peer-reviewed journal with a high impact factor. This 
variety of interests requires good communication between the consortium partners and careful 
management of the timing of the publications and patent applications. 
It is self-evident that these issues need to be addressed in a dedicated clause in the consortium 
agreement. Generally, such publication clauses no longer pose significant problems. It is generally 
accepted that parties agree on a ‘reasonable’ delay of publications in order to provide industry 
partners with a realistic timeframe to obtain a patent. However, in practice it is often unclear what 
reasonable means. Companies generally push for a longer period, ranging from three months (which 
is an absolute minimum for most companies to draft a decent patent application) to a year (which is 
considered to be the maximum for universities).  
In addition, some companies try to impose a review period, because they want to retain some 
oversight of what is being published (although some professors might object to this, because they 
disfavour commercialisation of university research). The review period should be kept short (e.g. one 
or two months) and it should be clear that in the absence of any objections or remarks publication 
should not be delayed any further and can be pursued. For instance, a company might want to 
exclude certain information from the publication when that information is considered confidential 
and not disclosed in the patent application. TTOs will often protest against withholding such 
information because it would violate academic freedom. Therefore, it is key for companies to identify 
early on what they consider confidential business information and to collaborate with scientists that 
have some understanding of the importance of IP and know-how and are willing to accept a certain 
limitation of their academic freedom in exchange for the benefit of a fruitful, potentially long-term 
collaboration with their commercial partners.  
